Drug Trial Radar · NCT01401647
Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,024
Actual
Start
May 2012
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada; American Heart Association; Defence Research and Development Canada; U.S. Army Medical Research and Development Command
- First posted
- Jul 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
Conditions
- Cardiac Arrest
Interventions
amiodaroneDrug
300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
LidocaineDrug
120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
Normal salineOther
6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Survive From the Time of Cardiac Arrest to Hospital DischargeTime frame: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Resuscitation Center
Birmingham, Alabama
UCSD-San Diego Resuscitation Center
San Diego, California
Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University
Portland, Oregon
The Pittsburgh Resuscitation Network, University of Pittsburgh
Pittsburgh, Pennsylvania
Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Center
Dallas, Texas
Seattle-King County Center for Resuscitation Research, University of Washington
Seattle, Washington
Milwaukee Resuscitation Network, Medical College of Wisconsin
Milwaukee, Wisconsin
University of Ottawa/University of British Columbia Collaborative RCC, Ottawa Health Research
Ottawa, Ontario, Canada
Toronto Regional Resuscitation Research Out-of-Hospital Network, University of Toronto
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.